Clinical Trial Update: Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a tumor antigen-pulsed autologous dendritic cell vaccine administered subcutaneously or intranodally in patients with multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tumor antigen-pulsed autologous dendritic cell vaccine

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED